{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:04:56Z","timestamp":1784775896112,"version":"3.55.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi250721-4\"><jats:title>Importance<\/jats:title><jats:p>While remission from clinical high risk (CHR) for psychosis is a favorable outcome, it is not well characterized over time.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250721-5\"><jats:title>Objective<\/jats:title><jats:p>To examine remission incidence, prevalence, and stability, and their association with demographic, clinical, medication, and cognitive variables, comparing 2 commonly used definitions.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250721-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This cohort study examined data from individuals aged 12 to 30 years at CHR in the North American Prodromal Longitudinal Study 3, collected from 9 sites across the US from February 2015 to November 2018. Statistical analyses were conducted between January 2023 and May 2025.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250721-7\"><jats:title>Exposure<\/jats:title><jats:p>CHR status using 2 definitions: (1) a symptoms-only definition based on the positive symptoms from the Scale of Prodromal Symptoms and (2) a symptoms-and-function definition based on positive symptoms and the modified Global Assessment of Functioning.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250721-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcomes were remission incidence, prevalence, and stability for 7 follow-up visits over 2 years. Associations of remission with age, sex at birth, race, antipsychotic and antidepressant medication, history of trauma, and cognitive performance were determined using mixed-effects logistic regression.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250721-9\"><jats:title>Results<\/jats:title><jats:p>The sample included 692 individuals (mean [SD] age, 18.7 [4.1] years; 319 female [46%]) at baseline, with 614 completing at least 1 follow-up. For the symptoms-only definition, 7% (95% CI, 5%-10%) met remission criteria after 2 months, 34% (95% CI, 31%-38%) met remission criteria at least once during the study, and 26% (95% CI, 22%-29%) met criteria at their last visit. The symptoms-and-function definition was associated with a lower remission incidence and prevalence, with 4% (95%CI, 2%-5%) meeting remission criteria after 2 months, 21% (95% CI, 18%-24%) meeting criteria at least once, and 15% (95% CI, 13%-18%) meeting criteria at their last visit. Under the symptoms-only definition, 83 of 153 individuals at CHR with at least 1 follow-up after remission (54%; 95% CI, 46%-62%) were stable remitters. Under the symptoms-and-function definition, 43 of 91 individuals (47%; 95% CI, 37%-58%) were stable remitters. The chance of staying in remission rose drastically once a person had more than 1 previous recorded remission visit. Higher functioning was associated with higher likelihood of remission (current score for symptoms only: OR, 1.04; 95% CI, 1.01-1.08; current score for symptoms and function: OR, 1.08; 95% CI, 1.02-1.14). More symptoms at baseline was associated with a lower likelihood of remission (general symptoms for symptoms only: OR, 0.77; 95% CI, 0.70-0.84; general symptoms for symptoms and function: OR, 0.80; 95% CI, 0.69-0.92).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250721-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>These findings suggest that CHR status is a dynamic state and that vulnerability can persist even after functional remission. Hence, continued follow-up and facilitated reengagement with clinical services after remission are essential.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.25644","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:00:29Z","timestamp":1754406029000},"page":"e2525644","source":"Crossref","is-referenced-by-count":6,"title":["Incidence, Prevalence, and Stability of Remission in Individuals With Clinical High Risk for Psychosis"],"prefix":"10.1001","volume":"8","author":[{"given":"Johanna","family":"Seitz-Holland","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Mass General Brigham, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace R.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mass General Brigham, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Reinen","sequence":"additional","affiliation":[{"name":"IBM Research, T.J. Watson Research Laboratory, Yorktown Heights, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mathalon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco"},{"name":"San Francisco Veterans Affairs Health Care System, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Corcoran","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Mental Illness Research, Education and Clinical Center, James J. Peters VA Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Reichenberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Vangel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mass General Brigham, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Penzel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mass General Brigham, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Ik K.","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mass General Brigham, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Castro","sequence":"additional","affiliation":[{"name":"IBM Research, T.J. Watson Research Laboratory, Yorktown Heights, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Haidar","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mass General Brigham, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Addington","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Kapur","sequence":"additional","affiliation":[{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Bouix","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mass General Brigham, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Software Engineering and Information Technology, \u00c9cole de Technologie Sup\u00e9rieure, Universit\u00e9 du Qu\u00e9bec, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie E.","family":"Bearden","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Biobehavioral Sciences and Psychology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"},{"name":"Institute of Behavioral Science, Feinstein Institutes for Medical Research, Manhasset, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D.","family":"McGorry","sequence":"additional","affiliation":[{"name":"Orygen, Parkville, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Woods","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut"},{"name":"Connecticut Mental Health Center, New Haven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnaby","family":"Nelson","sequence":"additional","affiliation":[{"name":"Orygen, Parkville, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 S.","family":"Kahn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha E.","family":"Shenton","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mass General Brigham, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo A.","family":"Cecchi","sequence":"additional","affiliation":[{"name":"IBM Research, T.J. Watson Research Laboratory, Yorktown Heights, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Pasternak","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mass General Brigham, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"issue":"33","key":"zoi250721r1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1192\/S0007125000297602","article-title":"Prediction of psychosis. A step towards indicated prevention of schizophrenia.","volume":"172","author":"Yung","year":"1998","journal-title":"Br J Psychiatry Suppl"},{"issue":"1","key":"zoi250721r2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamapsychiatry.2013.269","article-title":"The psychosis high-risk state: a comprehensive state-of-the-art review.","volume":"70","author":"Fusar-Poli","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"zoi250721r3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jamapsychiatry.2013.1270","article-title":"Long-term follow-up of a group at ultra high risk (\u201cprodromal\u201d) for psychosis: the PACE 400 study.","volume":"70","author":"Nelson","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi250721r4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.schres.2015.11.026","article-title":"Declining transition rates to psychotic disorder in \u201cultra-high risk\u201d clients: investigation of a dilution effect.","volume":"170","author":"Hartmann","year":"2016","journal-title":"Schizophr Res"},{"key":"zoi250721r5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.schres.2018.12.047","article-title":"Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: a systematic review.","volume":"210","author":"Beck","year":"2019","journal-title":"Schizophr Res"},{"issue":"3","key":"zoi250721r6","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/eip.13002","article-title":"Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population.","volume":"15","author":"Polari","year":"2021","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"zoi250721r7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/eip.12917","article-title":"Predictors of remission from the ultra-high risk state for psychosis.","volume":"15","author":"Glenth\u00f8j","year":"2021","journal-title":"Early Interv Psychiatry"},{"key":"zoi250721r8","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.770774","article-title":"Prediction and prevention in the clinical high-risk for psychosis paradigm: a review of the current status and recommendations for future directions of inquiry.","volume":"12","author":"Worthington","year":"2021","journal-title":"Front Psychiatry"},{"key":"zoi250721r9","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796021000639","article-title":"Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis.","volume":"31","author":"Salazar de Pablo","year":"2022","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"5","key":"zoi250721r10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/schbul\/sbw018","article-title":"Four-year follow-up of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: the Dutch early detection intervention evaluation (EDIE-NL) trial.","volume":"42","author":"Ising","year":"2016","journal-title":"Schizophr Bull"},{"issue":"2-3","key":"zoi250721r11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.schres.2014.04.002","article-title":"Symptomatic and functional remission of subjects at clinical high risk for psychosis: a 2-year naturalistic observational study.","volume":"156","author":"Lee","year":"2014","journal-title":"Schizophr Res"},{"issue":"10","key":"zoi250721r12","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1017\/S0033291718002258","article-title":"Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis.","volume":"49","author":"Addington","year":"2019","journal-title":"Psychol Med"},{"issue":"2","key":"zoi250721r13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1176\/appi.ajp.2019.18111290","article-title":"Characterizing covariant trajectories of individuals at clinical high risk for psychosis across symptomatic and functional domains.","volume":"177","author":"Allswede","year":"2020","journal-title":"Am J Psychiatry"},{"key":"zoi250721r14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.schres.2018.01.022","article-title":"Clinical trajectories in the ultra-high risk for psychosis population.","volume":"197","author":"Polari","year":"2018","journal-title":"Schizophr Res"},{"issue":"1-3","key":"zoi250721r15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.schres.2014.06.022","article-title":"Current status specifiers for patients at clinical high risk for psychosis.","volume":"158","author":"Woods","year":"2014","journal-title":"Schizophr Res"},{"issue":"2","key":"zoi250721r17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/schbul\/sbab115","article-title":"Individualized prediction of prodromal symptom remission for youth at clinical high risk for psychosis.","volume":"48","author":"Worthington","year":"2022","journal-title":"Schizophr Bull"},{"key":"zoi250721r18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.schres.2018.08.032","article-title":"Longitudinal changes in social cognition in individuals at clinical high risk for psychosis: an outcome based analysis.","volume":"204","author":"Shakeel","year":"2019","journal-title":"Schizophr Res"},{"key":"zoi250721r19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.schres.2017.05.032","article-title":"Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort.","volume":"192","author":"Kline","year":"2018","journal-title":"Schizophr Res"},{"issue":"18","key":"zoi250721r20","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1002\/hbm.26021","article-title":"Automatic auditory processing features in distinct subtypes of patients at clinical high risk for psychosis: forecasting remission with mismatch negativity.","volume":"43","author":"Wu","year":"2022","journal-title":"Hum Brain Mapp"},{"key":"zoi250721r21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.schres.2020.06.018","article-title":"Cognitive dysfunction in a psychotropic medication-na\u00efve, clinical high-risk sample from the ShangHai-at-risk-for-psychosis (SHARP) study: associations with clinical outcomes.","volume":"226","author":"Cui","year":"2020","journal-title":"Schizophr Res"},{"key":"zoi250721r22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3389\/fpsyt.2020.00770","article-title":"Mismatch negativity predicts remission and neurocognitive function in individuals at ultra-high risk for psychosis.","volume":"11","author":"Fujioka","year":"2020","journal-title":"Front Psychiatry"},{"issue":"1","key":"zoi250721r23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00406-016-0764-8","article-title":"Course of clinical high-risk states for psychosis beyond conversion.","volume":"268","author":"Michel","year":"2018","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"zoi250721r24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1046\/j.0001-690X.2003.00217.x","article-title":"Childhood abuse as a risk factor for psychotic experiences.","volume":"109","author":"Janssen","year":"2004","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"zoi250721r25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"3","key":"zoi250721r26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/0734282912467756","article-title":"Review of the Wechsler Abbreviated Scale of Intelligence, second edition (WASI-II).","volume":"31","author":"McCrimmon","year":"2013","journal-title":"J Psychoeduc Assess"},{"key":"zoi250721r27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.eurpsy.2019.08.005","article-title":"Clinical and functional ultra-long-term outcome of patients with a clinical high risk (CHR) for psychosis.","volume":"62","author":"Beck","year":"2019","journal-title":"Eur Psychiatry"},{"issue":"6","key":"zoi250721r28","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/schbul\/sbr098","article-title":"Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis.","volume":"38","author":"Schlosser","year":"2012","journal-title":"Schizophr Bull"},{"issue":"8","key":"zoi250721r29","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1176\/appi.ajp.2011.10081191","article-title":"At clinical high risk for psychosis: outcome for nonconverters.","volume":"168","author":"Addington","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"4","key":"zoi250721r30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1176\/ps.62.4.pss6204_0411","article-title":"The assessment of symptom severity and functional impairment with DSM-IV axis V.","volume":"62","author":"Smith","year":"2011","journal-title":"Psychiatr Serv"},{"key":"zoi250721r31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.schres.2021.11.032","article-title":"The associations between attenuated psychosis symptoms and functioning in Black and White youth at clinical high-risk for psychosis.","volume":"253","author":"Rakhshan Rouhakhtar","year":"2023","journal-title":"Schizophr Res"},{"issue":"12","key":"zoi250721r32","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jamapsychiatry.2023.2841","article-title":"Association of childhood area-level ethnic density and psychosis risk among ethnoracial minoritized individuals in the US.","volume":"80","author":"Anglin","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"zoi250721r33","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/eip.13062","article-title":"Clinical staging for youth at-risk for serious mental illness: A longitudinal perspective.","volume":"15","author":"Addington","year":"2021","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"zoi250721r34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/schbul\/sbw152","article-title":"The role of cognition and social functioning as predictors in the transition to psychosis for youth with attenuated psychotic symptoms.","volume":"43","author":"Addington","year":"2017","journal-title":"Schizophr Bull"},{"issue":"10","key":"zoi250721r35","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1176\/appi.ajp.2016.15070890","article-title":"An individualized risk calculator for research in prodromal psychosis.","volume":"173","author":"Cannon","year":"2016","journal-title":"Am J Psychiatry"},{"key":"zoi250721r36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.schres.2017.09.018","article-title":"Exploration of clinical high-risk dropouts.","volume":"195","author":"Stowkowy","year":"2018","journal-title":"Schizophr Res"},{"issue":"9","key":"zoi250721r37","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/eip.13514","article-title":"Identification of distinct clinical profiles and trajectories in individuals at high risk of developing psychosis: a latent profile analysis of the north American prodrome longitudinal study consortium-3 dataset.","volume":"18","author":"Berg\u00e9","year":"2024","journal-title":"Early Interv Psychiatry"},{"key":"zoi250721r16","volume-title":"The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-Up","author":"McGlashan","year":"2010"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837257\/seitzholland_2025_oi_250721_1753816529.80851.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:00:31Z","timestamp":1754406031000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.25644","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]}}}